Regenxbio says it plans to resubmit its gene therapy for Hunter syndrome to the U.S. Food and Drug Administration, and it intends to do so without running an additional study, according to Endpoints News.
The decision follows what Endpoints News describes as another apparent walk back by the FDA, which came after a round of leadership departures at the agency. According to Regenxbio, the FDA told the biotech that its existing data could support the resubmission — meaning the company would not need to generate fresh clinical evidence before bringing the application back to regulators.
Hunter syndrome is a rare, inherited genetic disorder. Gene therapies like the one Regenxbio is developing aim to treat such conditions by addressing their underlying genetic cause, an approach that has drawn intense interest because it offers the prospect of a one-time treatment for diseases that currently have few options.
The back-and-forth highlighted by Endpoints News underscores how much a company's path to market can hinge on the FDA's posture — and on who is making the decisions inside the agency. Shifts in agency leadership can translate into shifting signals for the biotechs waiting on its rulings.
For patients and families affected by Hunter syndrome, the practical stakes are timing: a resubmission that relies on existing data rather than a new trial could shorten the road to a potential approval, assuming regulators ultimately agree.
Why it matters: A drugmaker being told it can move forward on data it already has — rather than starting a costly new study — can mean the difference between a therapy reaching rare-disease patients soon or years from now.